Skip to main content
Caplight Logo









Intrommune Therapeutics

Intrommune Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://intrommune.com/

Last Round

Series A

Jun 9, 2021

Est. Valuation

$15.11M

Total Funding Raised

$5.51M

Company Overview

Intrommune Therapeutics is a biotechnology company that is developing a treatment platform for food allergies using oral mucosal immunotherapy (OMIT) delivered through a specially formulated toothpaste.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

oral mucosal immunotherapyOMITfood allergy treatmentpeanut allergy treatmentallergy toothpasteimmunotherapydrug delivery platformallergy desensitizationtoothpaste delivery systemclinical-stage biotechdirect-to-consumer advertising

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Intrommune Therapeutics Comparables

Compare Intrommune Therapeutics with similar companies based on industry and business-model similarity.

Intrommune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Moonlight Therapeutics
81%
Prota Therapeutics
78%
InnoUp Farma
78%

Intrommune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 9, 2021
CrowdfundingApr 12, 2018

Key People

Founding team and executive leadership

Michael Nelson

Founder & CEO

Founding Team

Intrommune Therapeutics Investors

Notable investors and investment history

Intrommune Therapeutics investors
InvestorRounds
Chemical Angel NetworkSeries A
Robin Hood VenturesSeries A
Red Bear VenturesSeries A
Timberline HoldingsSeries A
NetcapitalCrowdfunding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 20, 2026

    Monthly visitors increased 46% MoM.

  • Nov 6, 2025

    Monthly visitors increased 34% MoM.

Intrommune Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Intrommune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Intrommune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range14
Year Founded2015
Last FundingJun 9, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.